Physician profile
David B Leff
NPI 1619956505
$377,114.16
in general payments reported to CMS, 2019-2025
56 companies · $83K in 2025
The $83K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87K · 2020: $21K · 2021: $57K · 2022: $32K · 2023: $28K · 2024: $69K · 2025: $83K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $147K · Food and Beverage: $20K · Travel and Lodging: $11K · Education: $2,340 · Honoraria: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $146,612.16 |
| Food and Beverage | $19,559.09 |
| Travel and Lodging | $11,064.33 |
| Education | $2,339.99 |
| Honoraria | $360.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $155,140.42 | 2019-2025 | |
| Genzyme Corporation | $58,792.90 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57,873.57 | 2019-2024 | Xifaxan, Trulance, Relistor |
| Regeneron Healthcare Solutions, INC. | $33,764.34 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $31,529.71 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $7,263.51 | 2023-2025 | Zenpep |
| Allergan, INC. | $5,216.49 | 2019-2020 | |
| Ardelyx, INC. | $4,682.64 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $4,551.92 | 2024-2025 | Rezdiffra, Resmetirom |
| Shionogi INC | $4,304.22 | 2019 | |
| Alfasigma USA, INC. | $4,173.87 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $1,051.65 | 2019-2025 | Tremfya, Stelara |
| Janssen Biotech, INC. | $997.07 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Nestle Healthcare Nutrition INC. | $809.38 | 2020-2023 | |
| Lilly USA, LLC | $805.90 | 2023-2025 | Omvoh, Zepbound, Mounjaro |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $617.01 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $584.34 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $456.93 | 2019-2025 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $440.03 | 2023-2025 | Iqirvo, Bylvay |
| Daiichi Sankyo INC. | $438.94 | 2019-2024 | Injectafer |
| Ironwood Pharmaceuticals, INC | $367.42 | 2019-2023 | Linzess |
| Intercept Pharmaceuticals, INC. | $359.97 | 2019-2025 | Ocaliva |
| Celltrion USA INC. | $309.59 | 2024-2025 | Vegzelma |
| Lucid Diagnostics INC. | $292.83 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $183.96 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Boston Scientific Corporation | $172.14 | 2019-2025 | General - Therapies |
| Amgen INC. | $168.33 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $158.11 | 2020-2024 | Entyvio, Gattex |
| Medtronic, INC. | $154.75 | 2023 | Interstim |
| Redhill Biopharma INC. | $153.77 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.54 | 2019-2024 | Jardiance, Cyltezo |
| Celgene Corporation | $118.72 | 2021-2023 | Zeposia |
| Intuitive Surgical, INC. | $116.77 | 2025 | |
| Grifols USA, LLC | $111.24 | 2020-2022 | |
| Sobi, INC | $91.02 | 2021 | |
| Baxter Healthcare | $82.55 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| United Therapeutics Corporation | $79.42 | 2023-2025 | Tyvaso, Tyvaso |
| Pulmonx Corporation | $64.18 | 2025 | Zephyr Delivery Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Abbott Laboratories | $60.39 | 2023-2025 | Proclaim, Freestyle Libre 3 |
| Qol Medical, LLC | $54.10 | 2022-2025 | Sucraid, Sucraid |
| Covis Pharma Gmbh | $47.66 | 2021 | |
| Mylan Institutional INC. | $46.15 | 2023 | Hulio |
| Novo Nordisk INC | $31.11 | 2020-2025 | Wegovy |
| Impulse Dynamics (USA) INC. | $29.79 | 2022-2023 | Optimizer |
| Insmed, INC. | $26.69 | 2025 | Arikayce |
| Sunovion Pharmaceuticals INC. | $26.52 | 2019 | |
| Ucb, INC. | $23.54 | 2019 | |
| Biocon Biologics INC | $21.66 | 2025 | Yesintek |
| Actelion Pharmaceuticals US, INC. | $20.40 | 2024 | Opsumit |
| Advanced Respiratory, INC | $17.85 | 2021 | |
| Hologic Sales and Service, LLC | $17.38 | 2023 | Aptima |
| Organon LLC | $17.21 | 2023 | Hadlima, Renflexis |
| Electromed, INC. | $17.11 | 2025 | Smartvest |
| Ethicon US, LLC | $12.73 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.14 | 2019 | |
| Phadia US INC. | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Leff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.